|
NL2014935B1
(en)
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
|
HK1258444A1
(zh)
*
|
2015-10-09 |
2019-11-15 |
Immatics Biotechnologies Gmbh |
抗wt1/hla特异性抗体
|
|
MX2018004721A
(es)
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
CN109069627A
(zh)
*
|
2016-01-14 |
2018-12-21 |
纪念斯隆-凯特琳癌症中心 |
对foxp3衍生肽特异性的t细胞受体样抗体
|
|
AU2018219887B2
(en)
|
2017-02-08 |
2024-08-15 |
Dragonfly Therapeutics, LLC |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
CN110944661A
(zh)
|
2017-02-20 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
结合her2、nkg2d和cd16的蛋白质
|
|
JP7538601B2
(ja)
|
2017-04-26 |
2024-08-22 |
ユーリカ セラピューティックス， インコーポレイテッド |
キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
|
|
US12178830B2
(en)
|
2017-06-30 |
2024-12-31 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
|
JP7072792B2
(ja)
*
|
2017-12-11 |
2022-05-23 |
国立大学法人神戸大学 |
二重特異性抗体
|
|
MX2020006119A
(es)
|
2017-12-21 |
2020-08-24 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1.
|
|
CA3237846A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
BR112020015994A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
|
|
CN112041432A
(zh)
|
2018-02-15 |
2020-12-04 |
纪念斯隆-凯特林癌症中心 |
Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
JP2021526365A
(ja)
*
|
2018-05-18 |
2021-10-07 |
チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ |
改善された標的化ｔ細胞療法
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
KR102835308B1
(ko)
|
2018-08-08 |
2025-07-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
WO2021202908A1
(en)
*
|
2020-04-02 |
2021-10-07 |
The Board Of Regents Of The University Of Texas System |
Cd5l-binding antibodies and uses for the same
|
|
JP7512394B2
(ja)
|
2020-05-06 |
2024-07-08 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
|
|
KR20230074146A
(ko)
*
|
2020-09-24 |
2023-05-26 |
에프. 호프만-라 로슈 아게 |
T 세포 이중특이성 항체 관련 역효과의 예방 또는 완화
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
WO2023180346A1
(en)
*
|
2022-03-22 |
2023-09-28 |
Morphosys Ag |
Deimmunized antibodies specific for cd3
|